NOTION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
	This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
X	6. The computer readable form of the "Sequence Listing" is not the same as the paper copy of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
	7. Other:
Applicant Must Provide:	
X	An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
	An initial or <u>substitute</u> paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
X	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
Fo	r questions regarding compliance to these requirements, please contact:
Fo	r Rules Interpretation, call (703) 308-4216 r CRF Submission Help, call (703) 308-4212 tentIn Software Program Support
	Technical Assistance703-287-0200 To Purchase Patentin Software703-306-2600
	10 1 ulchase i alemini Collinare

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

reby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: U.S. Patent and Trademark Office, Box Sequence P.O. Box 2327, Arlington, VA 22202 on:

SUBMISSION UNDER 37 CFR §1.821 Docket No. SPO-115C1 Serial No. 09/888,035

SEQUENCE LISTING

February

David R. Saliwanchik, Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner

Cynthia E. Collins

Art Unit

1638

Applicant(s)

Atsunori Fukuda, Yoshiyuki Tanaka

FEB 1 4 2003

TECH CENTER 1600/2900

RECEIVED

Serial No.

09/888,035

Conf. No.

9222

Filed

June 22, 2001

For

Sodium/Proton Antiporter Gene

Box SEQUENCE U.S. Patent and Trademark Office P.O. Box 2327 Arlington, VA 22202

37 CFR §1.821 SUBMISSION OF SEQUENCE LISTING

Sir:

In compliance with 37 CFR §§1.821 through 1.825, transmitted herewith is a substitute sequence listing in computer readable form and on paper. A Second Notice to Comply with Sequence Requirements (mailed January 6, 2003) was received from the Patent and Trademark Office and a copy of the Notice is enclosed herewith.

I hereby certify that the attached sequence listing in computer readable form is identical to the attached paper copy of the sequence listing and that no new material is introduced by this submission.

Respectfully submitted,

David R. Saliwanchik

Patent Attorney

Registration No. 31,794

Phone No.:

(352) 375-8100

Address:

2421 N.W. 41st Street, Suite A-1

Gainesville, FL 32606

DRS/la

Attachments: Copy of Notice to Comply with Sequence Requirements

Sequence Listing on Paper

Sequence Listing in Computer Readable Form (disk)